

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
24 October 2024 (24.10.2024)



(10) International Publication Number
WO 2024/220546 A3

(51) International Patent Classification:

A61K 47/65 (2017.01) A61P 35/00 (2006.01)
A61K 47/68 (2017.01) C07K 16/30 (2006.01)

(21) International Application Number:

PCT/US2024/024997

(22) International Filing Date:

17 April 2024 (17.04.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/459,956 17 April 2023 (17.04.2023) US
63/459,961 17 April 2023 (17.04.2023) US

(71) Applicant: **PEAK BIO, INC.** [US/US]; 4900 Hopyard Road, Suite 100, Pleasanton, California 94588 (US).

(72) Inventors: **MITRA, Satyajit K.**; 4900 Hopyard Road, Suite 100, Pleasanton, California 94588 (US). **SAVAGE, Scott**; 4900 Hopyard Road, Suite 100, Pleasanton, California 94588 (US). **JAMMALAMADAKA, Vasu**; 4900 Hopyard Road, Suite 100, Pleasanton, California 94588 (US). **MONTEITH, William**; 4900 Hopyard Road, Suite 100, Pleasanton, California 94588 (US). **HUH, Hoyoung**; 4900 Hopyard Road, Suite 100, Pleasanton, California 94588 (US).

(74) Agent: **MICKELSON, John W.** et al.; Viksnins Harris Padys Malen LLP, 7900 International Drive, Suite 410, Bloomington, Minnesota 55425 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))


Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(88) Date of publication of the international search report:

02 January 2025 (02.01.2025)

(54) Title: ANTIBODIES AND ANTIBODY-DRUG CONJUGATES AND METHODS OF USE AND SYNTHETIC PROCESSES AND INTERMEDIATES



(I)

(57) Abstract: The invention provides anti-Trop2 antibodies, antibody-drug conjugates comprising an antibody conjugated (directly or through a linker) to a drug moiety of formula: and methods of using the antibody-drug conjugates to treat disease. The invention also provides methods to prepare the drug moieties, antibodies, and antibody-drug conjugates (e.g., ADCs of formula I). The invention also provides antibody-linker-drug intermediates and other intermediates and compounds disclosed herein as well as methods to prepare these antibody-linker-drug intermediates, other intermediates and compounds.

WO 2024/220546 A3